Höfner K
Klinik für Urologie und Kinderurologie, Ev. Krankenhaus Oberhausen.
Urologe A. 2003 Jun;42(6):793-800. doi: 10.1007/s00120-003-0363-y. Epub 2003 May 20.
Today, urgency and urge incontinence are both defined under the topic overactive bladder (OAB) whereby pure urge syndrome (pollakisuria, nocturia, and urgency) can easily lead to urge incontinence. Antimuscarinics still constitute the domain of treatment for overactive bladder. The pharmacological effect of modern substances consists of M2 or M3 muscarinic receptor blockade. This blockade prevents acetylcholine from connecting to these receptors and thus leads to a weakness or prevention of the detrusor muscle contraction. These groups of drugs are defined as muscarinic receptor antagonists, antimuscarinics, or anticholinergics. In addition to the muscarinic receptors, some drugs directly block the calcium channels in the cell membrane (calcium antagonists) which are classified as drugs with mixed effect. The presented paper gives an overview about the existing data on drugs approved in Germany whose clinical effect has been proven in randomized studies or are have stood the test of time in daily clinical practice.
如今,急迫性尿失禁和尿急均在膀胱过度活动症(OAB)这一主题下进行定义,其中单纯的尿急综合征(尿频、夜尿症和尿急)很容易导致急迫性尿失禁。抗毒蕈碱药物仍然是膀胱过度活动症的治疗领域。现代药物的药理作用包括对M2或M3毒蕈碱受体的阻断。这种阻断可防止乙酰胆碱与这些受体结合,从而导致逼尿肌收缩减弱或受到抑制。这些药物类别被定义为毒蕈碱受体拮抗剂、抗毒蕈碱药物或抗胆碱能药物。除了毒蕈碱受体外,一些药物还直接阻断细胞膜中的钙通道(钙拮抗剂),这些药物被归类为具有混合作用的药物。本文对德国已批准的药物的现有数据进行了概述,这些药物的临床疗效已在随机研究中得到证实,或在日常临床实践中经受住了时间的考验。